Close Menu

NEW YORK ─ Affinity Biosensors is developing an antimicrobial susceptibility testing platform to enable hospitals to make quicker decisions about prescribing antibiotics for patients with bloodstream infections.

The firm leverages resonant suspended cantilevers that measure the mass and concentration of microbes to provide results for the susceptibility of a pathogen to an antibiotic about four hours after a positive blood culture.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.